| scholarly article | Q13442814 |
| P50 | author | Bernard Allaouchiche | Q88620770 |
| P2093 | author name string | Dominique Breilh | |
| Emmanuel Boselli | |||
| Jeannette Texier-Maugein | |||
| Marie-Claude Saux | |||
| P2860 | cites work | Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. | Q54005690 |
| Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. | Q54017571 | ||
| Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. | Q54168335 | ||
| Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. | Q54346349 | ||
| Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. | Q54442418 | ||
| Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. | Q54444593 | ||
| Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. | Q54466586 | ||
| Carbapenems: past, present, and future | Q24634999 | ||
| Carbapenemases: the versatile beta-lactamases | Q24685034 | ||
| Overview of seizure-inducing potential of doripenem | Q28254469 | ||
| Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use | Q28299749 | ||
| Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections | Q28345630 | ||
| Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. | Q33751215 | ||
| Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients | Q33836550 | ||
| Comparative pharmacokinetics of the carbapenems: clinical implications | Q34053776 | ||
| Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy | Q34078480 | ||
| Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study | Q34112476 | ||
| Pharmacokinetics of ertapenem in healthy young volunteers. | Q34141850 | ||
| Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. | Q34468030 | ||
| Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials | Q34475273 | ||
| Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase | Q34522266 | ||
| Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (bla KPC) variants | Q34596735 | ||
| Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers | Q34883132 | ||
| Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin | Q35533543 | ||
| Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model | Q35758849 | ||
| Newer carbapenems for urinary tract infections | Q35885913 | ||
| Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia | Q36410139 | ||
| Comparative review of the carbapenems | Q36815085 | ||
| Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study | Q36880729 | ||
| Continuous infusion of beta-lactams. | Q36924963 | ||
| Carbapenems in the USA: focus on doripenem | Q36960048 | ||
| In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. | Q36993524 | ||
| Carbapenems: a potent class of antibiotics | Q37030838 | ||
| Parenteral carbapenems | Q37043637 | ||
| Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases | Q37120635 | ||
| In vitro antimicrobial activity of doripenem, a new carbapenem | Q37121257 | ||
| Doripenem: a review of its use in the treatment of bacterial infections. | Q37263205 | ||
| Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis | Q37333147 | ||
| New developments in carbapenems | Q37348751 | ||
| Pharmacokinetic issues for antibiotics in the critically ill patient | Q37399820 | ||
| Doripenem monohydrate, a broad-spectrum carbapenem antibiotic | Q37401472 | ||
| Activity of a novel carbapenem, doripenem, against anaerobic pathogens | Q37403090 | ||
| Doripenem: position in clinical practice | Q37503320 | ||
| Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe | Q38002952 | ||
| In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia | Q39477537 | ||
| An overview of the pharmacology of imipenem/cilastatin | Q39758549 | ||
| Meropenem pharmacokinetics and penetration into an inflammatory exudate | Q39816570 | ||
| Multiple-dose pharmacokinetics of imipenem-cilastatin | Q39849277 | ||
| Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients | Q40749626 | ||
| Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations | Q41153161 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis | Q41912139 | ||
| Characteristics of doripenem: a new broad-spectrum antibiotic | Q42049594 | ||
| Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock | Q42558993 | ||
| Diffusion of ertapenem into bone and synovial tissues. | Q42629280 | ||
| A Multicenter Comparative Study of Meropenem and Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections in Hospitalized Patients | Q42677494 | ||
| Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa | Q43111763 | ||
| Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients | Q43147926 | ||
| Relevance of resistance levels to carbapenems and integron-borne blaIMP-1, blaIMP-7, blaIMP-10 and blaVIM-2 in clinical isolates of Pseudomonas aeruginosa | Q43168664 | ||
| Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. | Q43190490 | ||
| Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). | Q43203100 | ||
| Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis | Q43580816 | ||
| A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults | Q43595316 | ||
| Meropenem and continuous renal replacement | Q43707193 | ||
| Tissue penetration of Meropenem in patients undergoing gynecologic surgery | Q43743957 | ||
| Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections | Q43890461 | ||
| A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults | Q43933899 | ||
| Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study | Q43996920 | ||
| Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections | Q44066002 | ||
| Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults | Q44183675 | ||
| A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia | Q44261936 | ||
| Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models | Q44299887 | ||
| Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy | Q44312895 | ||
| Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections | Q44404714 | ||
| Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study | Q44442591 | ||
| The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients | Q44736207 | ||
| In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae | Q44890369 | ||
| Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations | Q44931240 | ||
| Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. | Q44989494 | ||
| Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). | Q45020140 | ||
| Doripenem. | Q45968844 | ||
| Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. | Q46113955 | ||
| Ertapenem peritoneal fluid concentrations in adult surgical patients | Q46189699 | ||
| In vitro activity of doripenem against Acinetobacter baumannii clinical isolates | Q46269429 | ||
| Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections | Q46350390 | ||
| Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis | Q46472365 | ||
| Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery | Q46497112 | ||
| Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study | Q46538480 | ||
| Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study | Q46733446 | ||
| Meta-analysis: ertapenem for complicated intra-abdominal infections. | Q46759587 | ||
| The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis | Q46763845 | ||
| Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem | Q46798613 | ||
| Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). | Q46819792 | ||
| Intraabdominal tissue concentration of ertapenem | Q46882391 | ||
| Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli | Q46921577 | ||
| Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results | Q46942931 | ||
| Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia | Q46951637 | ||
| Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients | Q46989475 | ||
| Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics | Q48611808 | ||
| Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. | Q50898088 | ||
| Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. | Q51926298 | ||
| The utility of diffusion chambers as models for the description of drug disposition. | Q52429191 | ||
| Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. | Q53933241 | ||
| Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. | Q53979811 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | carbapenem antibiotic | Q410897 |
| P304 | page(s) | 1-17 | |
| P577 | publication date | 2013-02-01 | |
| P1433 | published in | Journal of Chemotherapy | Q15754073 |
| P1476 | title | Carbapenems | |
| P478 | volume | 25 |
| Q35617587 | A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? |
| Q38726679 | A Critical Review of Analytical Methods for Determination of Ertapenem Sodium |
| Q37438110 | Acinetobacter baumannii Isolated from Lebanese Patients: Phenotypes and Genotypes of Resistance, Clonality, and Determinants of Pathogenicity. |
| Q38350301 | Development of novel antibacterial drugs to combat multiple resistant organisms. |
| Q37538764 | Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa. |
| Q42104058 | Evaluation of different pretreatment protocols to detect accurately clinical carbapenemase-producing Enterobacteriaceae by MALDI-TOF. |
| Q92976668 | Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime |
| Q37643662 | Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia |
| Q38964046 | In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii |
| Q40704527 | Mechanisms of ertapenem resistance in Enterobacteriaceae isolates in a tertiary university hospital |
| Q38132217 | New antibiotics for bad bugs: where are we? |
| Q37119083 | Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis |
| Q62631045 | Organocatalytic Mannich Reactions on a Carbapenem Core - Synthesis of Mannich Bases and Bicyclic Diazanonanes |
| Q48139759 | Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study |
| Q90645341 | Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes |
| Q91720698 | Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens |
| Q98564455 | The stability of carbapenems before and after admixture to PMMA-cement used for replacement surgery caused by Gram-negative bacteria |
| Q64259776 | Genome plasticity favours double chromosomal Tn4401b-bla transposon insertion in the Pseudomonas aeruginosa ST235 clone |
| Q61806026 | Infections Caused by Carbapenem-Resistant : An Update on Therapeutic Options |
| Q64242151 | Risk Factors for Development of Carbapenem Resistance Among Gram-Negative Rods |
| Q64093355 | Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) |
Search more.